Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Large Decline in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 58,900 shares, a decline of 91.6% from the October 31st total of 702,600 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average trading volume of 1,540,000 shares, the days-to-cover ratio is presently 0.0 days.

Shuttle Pharmaceuticals Trading Down 2.3 %

Shares of SHPH stock traded down $0.02 during mid-day trading on Thursday, reaching $0.85. The stock had a trading volume of 64,233 shares, compared to its average volume of 455,357. The company has a market cap of $3.11 million, a price-to-earnings ratio of -0.20 and a beta of -1.32. Shuttle Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $4.95. The business has a fifty day moving average of $1.24.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.96) EPS for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .